

Epilogue:

Jonson left the company a few years ago. Yes, ok - there was some pressure behind it, but he can work under pressure after all and the authority's problem with the study design, he never understood. The overpriced and time-consuming recruiting of the additional trial centres was certainly excessive. Well, he corrected the number of cases downwards a little. His statistician was not very happy about it, no sense for the entrepreneurial necessities. It is not his fault that the competition came to the market faster at the finishing line, that the remaining patent term was no longer sufficient to achieve a "return of investment", he was already no longer on board, if only they had let him continue. Lower case numbers, lower failure rate, higher quality of patient recruitment, with the usual high quality of his work, it would have worked out in the end. With these thoughts, he decided to end today, put the tool in the shed and left the garden.